drugset / Trial / NCT00002737

Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer

NCT00002737

RandomizedTreatment

Summary

RATIONALE: Interferon alfa may interfere with the growth of the cancer cells and slow the growth of kidney cancer. Isotretinoin may help kidney cancer cells develop into normal cells. It is not yet known whether interferon alfa plus isotretinoin is more effective than interferon alfa alone for kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without isotretinoin in treating patients who have metastatic kidney cancer.

Timeline

Start
1996-03
Primary completion
2001-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Isotretinoin Other / unclassified 1 mg/kg Oral
Background interferon alfa Protein / enzyme biologic 9e+06 iu Subcutaneous

Indications